Navigation Links
New pyrimidine compounds may lead to improved treatments for childhood brain cancer
Date:4/6/2010

April 6, 2010 (Philadelphia, PA) -- Src (short for sarcoma) is a family of proto-oncogenic tyrosine kinases active in many cancer tumors, including medulloblastoma, the most common malignant cancer in children. Src represents one of the most promising targets for cancer therapy.

A recent study shows that pyrazolo-[3,4-d]pyrimidine-derivatives, designed to target Src, may be effective in interfering with the cell cycle and causing cancer cell death in medulloblastoma. The results were published in FASEB (The Journal of the Federation of American Societies for Experimental Biology) and were funded by the Sbarro Health Research Organization Center for Biotechnology (www.shro.org), a nonprofit group devoted to molecular and genetic research located at the College of Science and Technology at Temple University in Philadelphia, PA and the Human Health Foundation (www.hhfonlus.org), a nonprofit biotechnology research organization located in Terni, Italy.

"Our aim was to investigate the inhibitory effects of new pyrimidine-derivatives," said lead author Antonio Giordano, M.D. PhD, the Founder and Director of the Sbarro Institute for Cancer Research and Molecular Medicine and a 'Chiara fama' Professor at the Department of Human Pathology and Oncology, University of Siena, Siena, Italy. "Our findings show that, in medulloblastoma cells, pyrimidine derivatives can downregulate Src activity and reduce cell proliferation and tumor progression in vivo. This suggests that pyrimidine derivatives could be an effective therapeutic strategy not only for the treatment of medulloblastomas, but also for other Src expressing tumors."

Although better treatment regimens, including surgery, chemotherapy and radiotherapy have substantially improved survival, medulloblastoma remains incurable in about one third of patients and current treatments can cause toxic neurocognitive side effects.

"Compared with conventional chemotherapeutic agents cisplatin and etoposide that are presently used in medulloblastoma therapy, we found that these pyrimidine derivatives show major inhibitory effects on cell proliferation," said Alessandra Rossi, Ph.D, a co-author of the study, a Research Fellow at the Sbarro Institute. "Using these compounds with radiotherapy could allow the reduction of radiation doses and, consequently, the avoidance of radiotherapy-related cognitive and endocrine toxic effects. Moreover, our findings reveal that the pyrimidine compounds showed synergistic effects when combined with cisplatin and etoposide, suggesting their possible use in association with chemotherapy."

Attempts to further reduce the morbidity and mortality associated with medulloblastoma have been limited by the toxicity of conventional treatments and the low permeability of the blood-brain barrier (BBB), which restricts the entry of hydrophilic and large liphophilic compounds into the brain.

"Other Src inhibitors, currently in clinical trials for the treatment of other pathologies, showed low efficacy in the treatment of metastasis to the brain," said co-author Silvia Schenone, Ph.D, Associate Professor at the University of Genoa, Genoa, Italy, in collaboration with Maurizio Botta, Ph.D, Adjunct Professor at Temple University, Director, Drug Discovery Program, Professor Medical Chemistry and Dean of the Faculty of Pharmacy at the University of Siena, Siena, Italy. "But our pyrimidine derivatives have liphophilic characteristics, which enable them to pass through the blood brain barrier more easily, representing an other advantage of their use in medulloblastoma therapy."

Besides the possible use of these pyrimidine derivatives in the treatment of medulloblastoma, these compounds could be useful to develop new pharmacologic inhibitors to study the physiological and oncogenic functions of Src.


'/>"/>

Contact: Ilene Rush
irush@shro.org
215-470-2998
Sbarro Health Research Organization
Source:Eurekalert

Related medicine news :

1. Sigma-Aldrich Reaches Agreement to Sell Pfizers Bioactive Small Molecule Compounds
2. Compounds Identified That Might Treat Nerve Diseases
3. Prenatal exposure to flame-retardant compounds affects neurodevelopment of young children
4. Marijuana Compounds Could Beat Back Brain Cancer
5. Spice Compounds May Stem Tumor Growth
6. Foster care associated with improved growth, intelligence compared to orphanage care
7. Improved device provides more rapid, comprehensive analysis of circulating tumor cells
8. Improved patient care with telemonitoring
9. Improved doctor-pharmacist collaboration needed: study
10. An improved method for calculating tumor growth
11. TeraMedica Unveils Improved Univision, Now Offering a Multi-Layer Enterprise Viewing Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... ... (ONS) wanted to create a communications platform that positions them as the go-to ... and ONS reinvented their online publication as an always-on, always-fresh news, views and ...
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro Health (“GH”) ( ... patients for colonoscopy at the HyGIeaCare® Center that is to be located adjacent ... , The HyGIeaCare® Prep, cleared by the U.S. Food and Drug Administration ...
(Date:3/24/2017)... ... , ... “Vintage and Harvest A Cultivation of Christian Love” is the creation ... North Carolina with his wife, Anna Marie. He and his wife are the proud ... also the author of “Shadow and Substance.” , “Love, the agape kind, is seen ...
(Date:3/23/2017)... , ... March 23, 2017 , ... The physicians of ... in the greater Houston Area. The new location is located at 2255 E. Mossy ... in Springwoods Village. This newest location will provide patients living in the north Houston ...
(Date:3/23/2017)... ... ... The MBI “Hall of Fame” recognizes the contributions of those whose careers are or were ... careers of all others involved. , On Monday, March 21st, 2017 Laurie Robert, ... Fame. The induction took place during the World of Modular – Award Gala in ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... Strategic Business Report" report to their offering. ... The report provides separate comprehensive analytics for the ... Europe , Asia-Pacific , Latin ... provided for the period 2015 through 2022. Also, a six-year historic analysis ...
(Date:3/24/2017)... -- HealthMine surveys with 9,250 insured consumers fielded from February ... want help from their plans in five key areas: ... 2) help closing gaps in care, 3) better digital ... relevant, real-time guidance. Meeting these needs is essential to ... A Reason to Stay Engaged in Health ...
(Date:3/24/2017)... and GENEVA , March 24, ... World Tuberculosis Day revitalizes efforts to develop sutezolid as ... On World Tuberculosis Day, TB Alliance and the Medicines ... clinical development of sutezolid, an antibiotic drug candidate which ... to the development of sutezolid in combination with other ...
Breaking Medicine Technology: